Condition 1: Hemodialysis. Condition 2: Chronic kidney disease (CKD). Condition 3: Hemodialysis. Encounter for adequacy testing for hemodialysis Chronic kidney disease, stage 5 Dependence on renal dialysis
Conditions
Interventions
Intervention 1: Intervention group: In the hemodialysis center, patients who meet the inclusion criteria are randomly divided into two groups of intervention and control after obtaining informed conse
Sponsors
Mashhad University of Medical Sciences
SabzDarman Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: patients who are on hemodialysis treatment 3 times a week for at least 6 months
Exclusion criteria
Exclusion criteria: Active stable angina History of myocardial Infarction (MI) in the previous month Congestive Heart Failure (CHF) (grade III, IV) Chronic hyperkalemia Active liver disease Musculoskeletal disorders Lower limb amputation Vascular access disorders Resistant Hypertension History of surgery in the previous month Peripheral neuropathy Dementia Malignancies Active Inflammation (Parathormone)PTH>1000 History of femur fraction Poor control diabetes mellitus Intake of immunosuppressant drugs tempreture>38' Hemodynamic disorders Cerebrovascular disease Active lung disease CardiacEjection Fraction (EF)<45% Hemoglobin<10 g/dL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lower Limb Strength. Timepoint: Measuring the duration of Sit-to-Stand 10 test at the beginning of study (before intervention), 3 and 6 months after cycling during hemodialysis (intervention). Method of measurement: Chronometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dialysis Adequacy. Timepoint: Measuring ?dialysis adequecy at the beginning of study (before intervention), 3 and 6 months after cycling during hemodialysis (intervention). Method of measurement: Measuring the levels of Urea before and after a dialysis session and calculating dialysis adequacy by collecting blood sample and measuring them with biochemical autoanalyzer.;Score of quality of life in Kidney Disease Quality of Life Instrument (KDQOL-36). Timepoint: Measuring the score of quality of life with Kidney Disease Quality of Life Instrument (KDQOL-36) at the beginning of study (before intervention), 3 and 6 months after cycling during hemodialysis (intervention). Method of measurement: Kidney Disease Quality of Life Instrument (KDQOL-36) Questionnaire.;High-sensitivity C-Reactive Protein (hs-CRP). Timepoint: Measuring the plasma levels of High-sensitivity C-Reactive Protein (hs-CRP) at the beginning of study (before intervention), 3 and 6 months after cycling during hemodialysis (intervention). Method of measurement: Measuring the plasma level of High-sensitivity C-Reactive Protein (hs-CRP) by venous blood sampling and measuring them with biochemical autoanalyzer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Arash Sefidgaran
Mashhad University of Medical Sciences
Outcome results
None listed